Study finds cancer-fighting goodness in cholesterol

April 19, 2012

A Simon Fraser University researcher is among four scientists who argue that cholesterol may slow or stop cancer cell growth. They describe how cholesterol-binding proteins called ORPs may control cell growth in A Detour for Yeast Oxysterol Binding Proteins, a paper published in the latest issue of the Journal of Biological Chemistry.

The scientists came to their conclusion while trying to understand how cholesterol moves around inside cells in the fat's journey to cell surfaces where it reinforces their outer membrane.

"The assumption was that ORPs bind and transport cholesterol inside cells in a similar fashion to how lipoproteins bind and move around the fat outside cells through the blood stream," explains Chris Beh. The SFU associate professor of molecular biology and biochemistry co-authored this paper.

Beh and his colleagues noted that engineered by them block the ability of ORPs to bind cholesterol but don't stop ORPs from functioning. In fact, these altered ORPs work better and activate other regulator proteins, which in turn trigger a variety of cellular processes that stimulate cell growth.

The scientists believe this happened because cholesterol-binding normally interferes with ORPs' ability to bind to another lipid or fat called PI4P, which is important for cell growth.

"That told us that ORPs probably have nothing to do with moving around cholesterol within cells," says Beh. "Rather cholesterol-binding puts the brakes on ORP's ability to bind to PI4P which, if left unchecked, could accelerate cell growth like crazy," says Beh. "Given that uncontrolled cell growth is a key feature of cancer, this means gaining a better understanding of the true purpose of cholesterol-binding within cells could be important in cancer treatment."

Beh and his colleagues draw on two important facts to support their conclusion.

"First, require ORPs to survive," explains Beh. "Second, other scientists have previously shown that a new class of natural compounds that look like steroids or cholesterol can kill a broad spectrum of different cancer cells."

Beh says he and his research partners will now find out exactly which proteins respond to ORP activation and under what circumstances does cholesterol turn off ORP's activation of them.

Explore further: Protein that directs cholesterol traffic identified

Related Stories

Protein that directs cholesterol traffic identified

February 20, 2012
(Medical Xpress) -- A protein that directs traffic within human cells has been identified as playing a key role in the accumulation of so-called “bad” cholesterol, according to a new study.

Lipid-modifying enzyme: New target for pan-viral therapeutics

December 7, 2011
Three different disease-causing viruses -- poliovirus, coxsackievirus, and hepatitis C -- rely on their unwilling host for the membrane platforms enriched in a specific lipid, phosphatidylinositol 4 phosphate (PI4P) on which ...

Eliminating the 'good cholesterol' receptor may fight breast cancer

April 3, 2012
Removing a lipoprotein receptor known as SR-BI may help protect against breast cancer, as suggested by new findings presented at the American Association for Cancer Research Annual Meeting 2012 by Jefferson's Kimmel Cancer ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.